ZYME - Zymeworks Inc.About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $51.93 | Open | $52.01 |
| Volume | 418.9K | Market Cap | 2.38B |
| Yield | Last Dividend |
| Zanidatamab Data Highlight Durable Antit... | 01/15/21 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated cl | |
| Raymond James Stick to Their Buy Rating ... | 01/13/21 |
| Raymond James Stick to Their Buy Rating for Zymeworks Inc | |
| Leerink Partners Stick to Their Buy Rati... | 01/12/21 |
| Leerink Partners Stick to Their Buy Rating for Zymeworks Inc | |
| Zymeworks Highlights 2020 Achievements a... | 01/11/21 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Announces Expansion of Zanidat... | 12/01/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothe... | |
| Zymeworks Receives Orphan Drug Designati... | 11/19/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothe... | |
| Zymeworks and ALX Oncology Announce Clin... | 11/16/20 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NA | |
| Raymond James Stick to Their Buy Rating ... | 11/04/20 |
| Raymond James Stick to Their Buy Rating for Zymeworks Inc | |
| Zymeworks Reports 2020 Third Quarter Fin... | 11/03/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks , Will stock surge before Earn... | 11/03/20 |
| Zymeworks announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Zymeworks Inc. (NYSE:ZYME) Sees Signific... | 10/21/20 |
| Zymeworks Inc. (NYSE:ZYME) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short... | |
| Zymeworks Inc. (NYSE:ZYME) Short Interes... | 10/21/20 |
| Zymeworks Inc. (NYSE:ZYME) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest ... | |
| Zymeworks Target of Unusually Large Opti... | 10/21/20 |
| Zymeworks Inc. (NYSE:ZYME) was the recipient of unusually large options trading on Monday. Traders acquired 1,032 put options on the stock. This repre... | |
| Zymeworks Sees Unusually High Options Vo... | 10/20/20 |
| Zymeworks Inc. (NYSE:ZYME) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 1,032 put options on the... | |
| Zymeworks Inc. (NYSE:ZYME) Sees Large De... | 10/20/20 |
| Zymeworks Inc. (NYSE:ZYME) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,98... | |
| Checkpoint Therapeutics, Nano-X Imaging ... | 09/11/20 |
| Gainers: Checkpoint Therapeutics (NASDAQ:CKPT) +29%, Nano-X Imaging (NASDAQ:NNOX) +21%, Biofrontera AG (NASDAQ:BFRA) +20%, Zymeworks (NYSE:ZYME) +14%,... | |
| Zymeworks to Present at Upcoming Investo... | 09/03/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Reports 2020 Second Quarter Fi... | 08/05/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Corporate Update Webcast and C... | 07/08/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Announces New Multispecific An... | 07/08/20 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longti | |
| Zymeworks Announces Corporate Update Web... | 06/30/20 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a w | |
| Zymeworks to Present at the Jefferies 20... | 05/28/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional thera... | |
| Zymeworks Reports 2020 First Quarter Fin... | 05/07/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Applied BioMath, LLC Announces Collabora... | 05/04/20 |
| CONCORD, Mass., May 4, 2020 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechani... | |
| Zymeworks Reports 2019 Year-End Financia... | 03/02/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks to Present at Raymond James 41... | 02/24/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therap... | |
| The Daily Biotech Pulse: Roche Reports P... | 01/23/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) ... | |
| Zymeworks Highlights 2019 Achievements a... | 01/13/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Announces Agreement with Pfize... | 01/12/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional thera... | |
| rating | 01/19/21 |
| Raymond James maintains Strong Buy rating and raises Price Target from $60.00 to $74.00 | |
| Strong Buy rating | 01/12/21 |
| SVB Leerink maintains Outperform rating and raises Price Target from $45.00 to $66.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
